Drug interactions
Glofitamab + Metformin-repaglinide
Severity: Moderate
Glofitamab and Metformin-repaglinide: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Glofitamab causes cytokine release that can transiently suppress CYP450 enzyme activity. This may raise exposure to CYP substrates such as repaglinide, with a risk of hypoglycemia. The effect is greatest around initial doses and during cytokine release syndrome.
What this interaction means in plain words
Glofitamab and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Glofitamab belongs to Oncology; Metformin-repaglinide belongs to Endocrine.
Why it happens
Cytokine-mediated suppression of CYP enzyme expression decreases repaglinide metabolism.
What to do
Monitor blood glucose during the first doses of glofitamab and during any cytokine release syndrome. Lower the repaglinide dose if hypoglycemia occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Glofitamab and Metformin-repaglinide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Metformin-repaglinide
Other interactions of Glofitamab
- Ergotamine + Glofitamab Major
- Glofitamab + Pimozide Major
- Bendamustine + Glofitamab Moderate
- Carbamazepine + Glofitamab Moderate
- Clomipramine + Glofitamab Moderate
- Clozapine + Glofitamab Moderate
Frequently asked questions
Can I take Glofitamab with Metformin-repaglinide?
MediHelp rates the interaction as moderate. Glofitamab and Metformin-repaglinide can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Glofitamab causes cytokine release that can transiently suppress CYP450 enzyme activity. This may raise exposure to CYP substrates such as repaglinide, with a risk of hypoglycemia. The effect is greatest around initial doses and during cytokine release syndrome.
How serious is the interaction between Glofitamab and Metformin-repaglinide?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose during the first doses of glofitamab and during any cytokine release syndrome. Lower the repaglinide dose if hypoglycemia occurs.
What other medicines interact with Metformin-repaglinide?
MediHelp also lists interactions of Metformin-repaglinide with, for example, Gemfibrozil, Apalutamide, Clarithromycin. The full list is on the Metformin-repaglinide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
